EIKN Stock — Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock (EIKN)

Updated October 16, 2026.

EIKN is a Stock. Total return is -50.5% over the past 0.7 years, 64.0 points behind SPY at 13.5%.

Eikon Therapeutics is a clinical biopharmaceutical company developing medicines for serious cancers and related conditions, with a pipeline including immune-activating agents, PARP inhibitors, a WRN helicase inhibitor, and androgen receptor antagonists across multiple indications. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to clinical-stage biopharmaceutical development with a higher risk and growth-oriented profile.

EIKN performance versus SPY

Price and return data through 2026-10-16.

Total return is -50.5% over the past 0.7 years, 64.0 points behind SPY at 13.5%.

EIKN key facts

Asset type

Stock

Asset class

Equity

Inception date

02/05/2026

Distribution frequency

None

Last close

$7.42 (as of 2026-10-16)

Market cap

$401,904,523

Average volume

482800.0

Payout ratio

0.0%

EPS

$-8.51

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

EIKN risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider EIKN — and who may not

It is a weaker fit for investors who need monthly cash flow (EIKN does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on EIKN

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions